多发性骨髓瘤特异性捕获测序平台发现了 IGLL5 中的新型易位和高频风险相关点突变。

A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5.

机构信息

Department of Medicine, Washington University School of Medicine, St. Louis, 63110, MO, USA.

Sage Bionetworks, Seattle, WA, 91809, USA.

出版信息

Blood Cancer J. 2018 Mar 21;8(3):35. doi: 10.1038/s41408-018-0062-y.

Abstract

Multiple myeloma (MM) is a disease of copy number variants (CNVs), chromosomal translocations, and single-nucleotide variants (SNVs). To enable integrative studies across these diverse mutation types, we developed a capture-based sequencing platform to detect their occurrence in 465 genes altered in MM and used it to sequence 95 primary tumor-normal pairs to a mean depth of 104×. We detected cases of hyperdiploidy (23%), deletions of 1p (8%), 6q (21%), 8p (17%), 14q (16%), 16q (22%), and 17p (4%), and amplification of 1q (19%). We also detected IGH and MYC translocations near expected frequencies and non-silent SNVs in NRAS (24%), KRAS (21%), FAM46C (17%), TP53 (9%), DIS3 (9%), and BRAF (3%). We discovered frequent mutations in IGLL5 (18%) that were mutually exclusive of RAS mutations and associated with increased risk of disease progression (p = 0.03), suggesting that IGLL5 may be a stratifying biomarker. We identified novel IGLL5/IGH translocations in two samples. We subjected 15 of the pairs to ultra-deep sequencing (1259×) and found that although depth correlated with number of mutations detected (p = 0.001), depth past ~300× added little. The platform provides cost-effective genomic analysis for research and may be useful in individualizing treatment decisions in clinical settings.

摘要

多发性骨髓瘤(MM)是一种涉及拷贝数变异(CNVs)、染色体易位和单核苷酸变异(SNVs)的疾病。为了能够在这些不同的突变类型之间进行综合研究,我们开发了一种基于捕获的测序平台,用于检测 MM 中改变的 465 个基因中的这些突变的发生情况,并使用该平台对 95 对原发性肿瘤-正常对进行测序,平均深度为 104×。我们检测到了超二倍体(23%)、1p 缺失(8%)、6q 缺失(21%)、8p 缺失(17%)、14q 缺失(16%)、16q 缺失(22%)和 17p 缺失(4%),以及 1q 扩增(19%)。我们还检测到了IGH 和 MYC 易位,其出现频率接近预期,NRAS(24%)、KRAS(21%)、FAM46C(17%)、TP53(9%)、DIS3(9%)和 BRAF(3%)中的非沉默 SNVs。我们发现 IGLL5 中经常发生突变(18%),这些突变与 RAS 突变互斥,并与疾病进展风险增加相关(p=0.03),这表明 IGLL5 可能是一种分层生物标志物。我们在两个样本中发现了新的 IGLL5/IGH 易位。我们对其中的 15 对进行了超深度测序(1259×),发现尽管深度与检测到的突变数量相关(p=0.001),但超过~300×的深度增加很少。该平台为研究提供了具有成本效益的基因组分析,并且在临床环境中可能有助于个体化治疗决策。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4b07/5862875/777e9766e919/41408_2018_62_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索